In Bacteriology, Hospital aquired infections, Real-time PCR

Excellent results of the RIDA®GENE MRSA real-time PCR assay in the external quality assessment program of Instand e.V.

Repeatedly, the R-Biopharm AG participated successfully in the INSTAND external quality assessment (EQA) program for PCR-/NAT MRSA/cMRSA (No. 539) in November 2015.

100% concurrence for true positive and true negative samples

The sample panel of the MRSA/cMRSA proficiency test consisted of two MRSA-positive samples and one MSSA mecA-dropout variant, as well as one negative sample (E. coli K12). One positive MRSA sample contained the mecC resistance gene.

All samples (4/4) were detected by all users of the RIDA®GENE MRSA assay resulting in 100% concurrence for true positive and true negative samples of the panel.

In contrast, of 298 participants using other test systems, only 50 – 83% identified the positive sample panel correctly. The results of the proficiency test are available on request from R-Biopharm AG.

The RIDA®GENE MRSA assay is listed by name since November 2014 with continuously increasing participant numbers. Click here to learn more about RIDA®GENE MRSA.

About MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of nosocomial infections worldwide (hospital-acquired MRSA also called HA-MRSA). Beside HA-MRSA infections also community-acquired MRSA infections (CA-MRSA) occur, which are acquired outside the hospital.


The R-Biopharm RIDA®GENE kits include all necessary components required for the specific detection of pathogens. An included extraction control ensures reliable results. All R-Biopharm RIDA®GENE kits are CE marked and are regularly evaluated by participation in the QCMD (Quality Control for Molecular Diagnostics) quality assessment.

Recent Posts

Start typing and press Enter to search

RIDAGENE Flu RIDAGENE Flu LC2.0 Influenza ImpfstammLegionella detection